key: cord-0275901-2b8fidi6 authors: Lecot, Pacôme; Ardin, Maude; Dussurgey, Sébastien; Alcazer, Vincent; Moudombi, Lyvia; Hubert, Margaux; Swalduz, Aurélie; Hernandez-Vargas, Hector; Viari, Alain; Caux, Christophe; Michallet, Marie-Cécile title: Gene signature of circulating platelet-bound neutrophils is associated with poor prognosis in cancer patients date: 2021-08-28 journal: bioRxiv DOI: 10.1101/2021.08.26.457803 sha: 7e2987dec8c463b012998eac8ed6e5574e1d5074 doc_id: 275901 cord_uid: 2b8fidi6 Beyond their critical role in hemostasis, platelets physically interact with neutrophils to form neutrophil-platelet aggregates (NPAs), enhancing neutrophil effector functions during inflammation. NPAs may also promote disease worsening in various inflammatory diseases. However, characterization of NPAs in cancer remains totally unexplored. Using ImageStream®X (ISX) imaging flow cytometer, we were not only allowed able to detect CD15+ CD14− CD36+ ITGA2B+ NPAs in both healthy donors’ (HDs) and cancer patients’ bloods, but we also showed that NPAs result from the binding of platelets preferentially to low-density neutrophils (LDNs) as opposed to normal-density neutrophils (NDNs). By re-analyzing two independent public scRNAseq data of whole blood leukocytes from cancer patients and HDs, we could identify a subset of neutrophils with high platelet gene expression that may correspond to NPAs. Moreover, we showed that cancer patients’ derived NPAs possessed a distinct molecular signature compared with the other neutrophil subsets, independently of platelet genes. Gene ontology (GO) term enrichment analysis of this NPAs-associated neutrophil transcriptomic signature revealed a significant enrichment of neutrophil degranulation, chemotaxis and trans-endothelial migration GO terms. Lastly, using The Cancer Genome Atlas (TCGA), we could show by multivariate Cox analysis that the NPAs-associated neutrophil transcriptomic signature was associated with a worse patient prognosis in several cancer types. These results suggest that neutrophils from NPAs are systemically primed by platelets empowering them with cancer progression capacities once at tumor site. NPAs may therefore hold clinical utility as novel non-invasive blood prognostic biomarker in cancer patients with solid tumors. Novelty and Impact Platelets physically interact with peripheral blood neutrophils to form neutrophil-platelet aggregates (NPAs), known to promote disease worsening in various inflammatory diseases. However, characterization of NPAs in cancer remains totally unexplored. We showed that NPAs-associated neutrophils were a yet-unreported unique subset of circulating neutrophils associated with a worse patient prognosis in several cancer types. NPAs may hold clinical utility as novel non-invasive blood prognostic biomarker in cancer patients with solid tumors. 6 extracellular traps (NETs) [19] [20] [21] and display increased phagocytic functions [22] [23] [24] . Furthermore, NPAs 121 display enhanced trans-endothelial migration capacity [25, 26] therefore promoting neutrophil infiltration to 122 site of injury and fueling pathological inflammation in various diseases [21, [27] [28] [29] . However, to our 123 knowledge, the characterization of NPAs in cancer patients remains unexplored. In this study, we showed that neutrophils from NPAs represent a unique subset of activated 126 neutrophils in cancer patients by combining ImageStream®X (ISX) imaging flow cytometry and analysis of 127 public single cell transcriptomic data of human circulating neutrophils. In particular, we showed that LDN 128 as opposed to NDN were preferentially involved in NPA formation. Finally, we could generate a specific 129 gene signature of neutrophils in NPAs that we found associated with a worse prognosis in pancreatic 130 adenocarcinoma patients and liver hepatocellular carcinoma patients. Human cohorts 135 Whole blood from a cohort of 6 metastatic NSCLC patients (Table S1 ) who gave informed consent at the 136 Léon Bérard Hospital (France), was collected in EDTA-coated tubes. As an age and sex-matched control 137 cohort, whole blood from healthy donors (HD) was collected via the Etablissement Français du Sang (Table 138 S1 ). 142 Blood from NSCLC patients or HD was withdrawn in EDTA-coated vacutainers 1 hour prior to the 143 processing. Two tubes of 3 ml of blood were centrifuged at 800 rpm (no brake) for 15 min at room 144 temperature (RT) to separate plasma from leukocyte-enriched red pellet. Platelet-rich plasma was 145 discarded for both tubes. One out of the two tubes was used for whole blood staining while the other served 146 for the separation of LDNs from NDNs. For such separation, leukocyte-enriched red pellet was re-147 suspended in 6 ml of PBS1X (5 mM EDTA) and then layered on the top of 3 ml of Ficoll (CMSMSL01-01, 7 EUROBIO), before being centrifuged at 1800 rpm for 20 min at RT (acceleration 5 and brake 1). LDNs-149 enriched PBMC ring and NDNs-enriched red pellet were washed with PBS1X, and pellets were re-150 suspended in BD Pharm Lyse™ (555899) according to manufacturer's protocol to eliminate red blood cells. In parallel, whole blood leukocyte-enriched red pellet was also re-suspended in BD Pharm Lyse™ for the 152 same purpose. After incubation, red blood cells (RBC)-lysed leukocytes were washed twice with PBS1X (5 153 mM EDTA) were re-suspended at a final concentration of 20.10 6 cells/ml prior to be stained. Samples were 154 acquired on ImageStream®X (ISX) no more than 5 days following cell staining and fixation. genes, using RunPCA function. We used JackStraw function to determine the statistical significance of 206 PCA scores that led us to retain the first 9 principal components (PCs). We next define the number of 207 clusters by using FindNeighbors and FindClusters functions that take into account the first 9 PCAs and a 208 resolution of 0.66, leading to 11 clusters. We ran the uniform manifold approximation and projection (UMAP) 209 dimensional reduction technique, using RunUMAP function, and then display 2D UMAP projections. We NPAs from NSCLC patients and HDs' whole blood were identified as CD15 + CD14neutrophils that 278 were double positive for platelet glycoprotein 4 (CD36) and integrin alpha-IIb (ITGA2B, also known as 279 CD41a) by using ImageStream®X (ISX) imaging flow cytometer ( Fig. 1A-B ). We could also easily identify NPA between NSCLC patients (mean frequency = 1.48%) and HDs (mean frequency = 1.16%), was roughly 285 the same, with no statistically significant difference (p value = 0.64), one NSCLC patient displayed more 286 than a three-fold increase of NPA proportion (mean frequency = 4.59%) compared to the mean frequency 12 of NPA in NSCLC patients and HDs (Fig. 1D) . Interestingly, among all 6 NSCLC patients analyzed, this 288 patient with high percentage of NPAs also displayed by far the highest NLR value (34.56 as opposed to 289 7.21 for the others), mostly explained by a higher absolute neutrophil count (Table S1) , and the highest 290 tumor burden (7 vs 2 metastatic sites in the rest of the cohort) (Table S1 ). Platelets preferentially bind to low-density neutrophils (LDNs), rather than normal-density 293 neutrophils (NDNs) in cancer patients' blood. Given the well-known detrimental role of LDNs in cancer [11] [12] [13] [14] 41 ,42], we next analyzed a 296 potential link between LDNs and NPAs. We first performed a single sample Gene Set Enrichment Analysis (ssGSEA) on publicly available 298 transcriptomic data of bulk LDNs and bulk NDNs from NSCLC and Head and Neck Cancer (HNC) patients' 299 blood (GSE79404). We showed that the published platelet-specific gene signature " Raghavachari" [43] 300 (Table S2 ) was significantly (p-value = 0.0022) more enriched in LDNs than in NDNs ( Fig. 2A ). We next isolated LDNs and NDNs (Fig. 2B ). Using ISX, we could visualize CD15 + CD14 -CD36 + 302 ITGA2B + NPAs from LDNs but not from NDNs ( We next aimed at characterizing NPAs from cancer patients at the transcriptomic level. Indeed, given the small size of platelets, we hypothesized that NPAs could be isolated as a single cell (Fig. 1B) , 311 just like free neutrophil, and therefore be present in scRNAseq data. For this purpose, we took advantage 312 of a recently published scRNAseq dataset of NSCLC patients' whole blood leukocytes (GSE127465) [31] . Therefore, for our analysis we used normalized counts tables and kept author's major cell type annotations 314 to identify blood cell populations. We could re-cluster all leukocytes (Fig. 3A ) and distinguished 6 clusters 13 of neutrophils (named Neu 1, Neu 2, Neu 3, Neu 4, Neu 5 and Neu 6 ( Fig. 3B ). Interestingly, we observed 316 that Neu 5 cluster seemed to be distinct from the other neutrophil clusters, through its close proximity with 317 the platelet cluster (Fig. 3B ). Using a published neutrophil-specific gene signature "Ponzetta" (Table S2) 3D) . We found that a fraction of the Neu 5 neutrophils as well as of monocytes were more 327 enriched for the platelet-specific gene signature than any other of the non-platelet cell types (Fig. 3D) . Looking at the gene level, PF4, PPBP and NRGN (Table S3 ) platelet genes were in the 5 most-differentially 329 upregulated genes (Table S4 ) able to discriminate the Neu 5 cluster from the other neutrophils and immune 330 cell clusters (Fig. 3F ). In conclusion, the Neu 5 cluster of platelet gene-expressing neutrophils seems to 331 correspond to NPAs. To validate that this Neu 5 cluster of platelet gene-expressing neutrophils containing NPAs was not 333 exclusive to this particular scRNAseq dataset, we next investigated for the presence of platelet gene-334 expressing neutrophils in a public scRNAseq dataset of HDs' whole blood leukocytes (GSE145230). By 335 performing the same analysis as for the NSCLC patients scRNAseq dataset (GSE127465), we were able 336 to identify a cluster of neutrophils (Neu 17) located in between the platelet cluster and the remaining 337 neutrophil clusters (Fig. S1A-B) . Consistent with what we previously found in the NSCLC patients In order to rule out that upregulation of platelet genes in neutrophils is not a consequence of 342 neutrophil activation, we next tested whether the enrichment of the platelet-specific genes signature Table S1 ). To next determine if neutrophils from the NPA cluster were distinct from any other subset of 367 neutrophils, we first performed a differential gene expression analysis of the NPA cluster (Neu 5 PPBP high 368 PF4 high NRGN high cells) in comparison to each individual neutrophil clusters (Fig. 4B) . We then took the 369 union of upregulated genes in NPA cluster from each pairwise comparison, therefore yielding 191 genes. We then removed the platelet genes (Fig. 4C ) and identified 120 non-platelet genes discriminating NPAs-371 derived neutrophils from any other subset of neutrophils. We next performed a pathway analysis and found a significant enrichment of neutrophil 374 degranulation/chemotaxis-related GO biological process, secretory granules-related GO cellular 375 component and trans-endothelial migration-related KEGG gene set (Fig. 4D) . Collectively, these data 376 demonstrate that NPAs-derived neutrophils display enhanced degranulation, chemotaxis and trans- (Fig. 5B ). Using scRNAseq data from human NSCLC tumor samples (discovery dataset) matching 387 previously-used patients' whole bloods [31] , we then eliminated RBPJ, IDH2, HELLPAR and CCNI that 388 were highly expressed by multiple other tumor-associated cell types (Fig. S4 ), thus yielding a final 12-genes 389 NPAs-associated neutrophil signature (Fig. 5B) . We next validated the specificity of this new NPAs-390 associated neutrophil signature in the discovery dataset (scRNAseq dataset from NSCLC tumors) by showing that cells coexpressing at least 3 out of the 12-genes NPA-associated neutrophil signature were 392 significantly more enriched in tumor-associated neutrophils than any other major cell types present in the 393 tumor microenvironment (Fig. 5C ). We next evaluated the prognostic value of the 12-genes NPAs-associated neutrophil signature 396 (Fig. 5B ) and the canonical neutrophil signature "Ponzetta" (Table S2 ) with a pan-cancer approach in the 397 TCGA database. By performing a multivariate Cox analysis, we did not find any association between the 398 16 NPAs-associated neutrophil signature and the prognosis of either types of NSCLC cancer patients, lung 399 squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) (Fig. 5D) . Nevertheless, we could find 400 that the signature was statistically associated with a worse progression-free interval (PFI) (p-value < 0.001, Hazard Ratio (HR) = 2.9) and overall survival (OS) (p-value < 0.001, HR = 2.6) in pancreatic 402 adenocarcinoma cancer patients (PAAD) (Fig. 5D and Fig. S5A ), as well as in liver hepatocellular LIHC cancer patients (Fig. 5F ). Whereas the canonical neutrophil signature "Ponzetta" did not show 409 statistically significant association with prognosis in PAAD cancer patients (Fig. 5E) , it was associated with 410 an opposite outcome in LIHC cancer patients (Fig. 5F ). This implies again that NPAs-associated neutrophils 411 are distinct from canonical neutrophils. Collectively, our results therefore suggest that a subset of Using ISX, we were able to distinguish and quantify accurately NPAs in our cohort of NSCLC cancer 427 patients and HDs. Although we did not find a significant difference in the percentage of NPAs between 428 NSCLC cancer patients and HD, one NSCLC patient displayed more than a three-fold increase of NPA 429 proportion compared to the mean frequency of NPAs in NSCLC patients and HDs (Fig. 1D) . Interestingly, 430 this patient also displayed the highest number of different metastatic sites (Table S1) , as well as an 431 extremely high NLR value of 34.56 (Table S1 ). This is consistent with the poorer clinical outcome of patients 432 with elevated NLR values, including NSCLC patients [47] . This high NLR value was mostly explained by a 433 massive increase in the absolute neutrophil count (ANC), rather than a decrease in the absolute lymphocyte Although unexpected, this study identified a yet unreported new subset of neutrophils in scRNAseq 456 data with high platelet gene expression that most likely correspond to NPAs. We ruled out the possibility 457 that platelet genes could be expressed by a subset of activated neutrophils as we did not find enrichment 458 of platelet signature in stimulated neutrophils (Fig. S2) . Moreover, it is also unlikely that neutrophils 459 expressing platelet genes correspond to a common progenitor of megakaryocyte (platelet-producing cell) 460 and neutrophils, as the closest common progenitor between the two is the common myeloid progenitor Table S4 ) and the platelet cluster (Table S3) (Table S5) . Table S6 ) and the 800 platelet cluster (Table S3) corresponds to the canonical neutrophil signature (annotated "Neutrophil_Ponzetta" -see Table S2 ) and 813 the 12-genes NPAs-associated neutrophil signature (annotated "NPA_12" -see Figure 5 .B). HR Adjusted p-values (Adj P) were displayed on graphs, **** Adj P ≤ 0.0001, *** Adj P ≤ 0.001, ** Adj P ≤ 0.01. Two dimensional-UMAP representation of individual neutrophil clusters (from NSCLC patients' whole blood 860 leukocytes from scRNAseq data (GSE127465)) whose projection was based on UMAP parameters used 861 to discriminate the major subsets of leukocytes. Figure S4 . Two dimensional-UMAP representation of NSCLC patients' tumor scRNAseq data. Expression of each of the 16 genes of the NPA signature (Table S5) List of 120 genes of the NPA signature generated based on public scRNAseq data from NSCLC patients' 887 whole blood leukocytes -GSE127465. C D E F **** ns ns ns ns ns **** **** **** **** **** **** **** ns * ns **** **** **** **** **** ns ns ns ** ns **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** Differential gene expression analysis Neu 5 PPBP high PF4 high NRGN high "NPA" Differential gene expression analysis **** **** **** **** ** **** **** **** **** **** **** **** ** **** **** **** **** **** **** **** ** **** RTN3 RAB3D IL10RB GPR82 SPAG9 B4GALT5 TMUB2 ZNF397 NXPE3 TRIM41 TSC22D4 YY1 Better prognosis Cells coexpressing at least 3 genes from the 12-genes NPAs-associated neutrophil signature Tumor subset Mutually upregulated genes (46 NPA genes) 12 NPAs-associated neutrophil genes Figure 5 Epithelial Carcinogenesis via Debridement of Hypoxic Tumor Cells Origin and Role of a 563 Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human 564 Lung Cancer Unconventional T Cells Mediate Resistance against Murine Sarcomas and Selected Human Tumors IL17-producing γδ T cells 569 and neutrophils conspire to promote breast cancer metastasis Neutrophils support lung colonization of metastasis-initiating breast cancer cells Neutrophil extracellular 573 traps produced during inflammation awaken dormant cancer cells in mice Prognostic role of 575 neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis A systematic review and meta-analysis on the impact of pre-578 operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours Optimal cut-off for neutrophil-to-581 lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients Neutrophil/lymphocyte 584 ratio has a prognostic value for patients with terminal cancer Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets Circulating neutrophil subsets in 590 advanced lung cancer patients exhibit unique immune signature and relate to prognosis Lectin-type 593 oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor 594 cells in cancer patients Phenotypic diversity and plasticity in 596 circulating neutrophil subpopulations in cancer Multidimensional imaging provides 598 evidence for down-regulation of T cell effector function by MDSC in human cancer tissue Osteoblasts remotely 601 supply lung tumors with cancer-promoting SiglecFhigh neutrophils Spleen mediates a distinct hematopoietic progenitor 603 response supporting tumor-promoting myelopoiesis Platelet P-selectin initiates cross-605 presentation and dendritic cell differentiation in blood monocytes Intravascular neutrophil extracellular traps 607 capture bacteria from the bloodstream during sepsis Platelet TLR4 activates 609 neutrophil extracellular traps to ensnare bacteria in septic blood Platelets induce 611 neutrophil extracellular traps in transfusion-related acute lung injury Circulating platelet-neutrophil 613 complexes represent a subpopulation of activated neutrophils primed for adhesion, phagocytosis and 614 intracellular killing Efficient phagocytosis 616 of periodontopathogens by neutrophils requires plasma factors, platelets and TLR2 Neutrophil Function Is Dysregulated by M Protein from Streptococcus pyogenes Platelets enhance neutrophil transendothelial migration 622 via P-selectin glycoprotein ligand-1 Platelets directly enhance neutrophil 624 transmigration in response to oxidised low-density lipoprotein Neutrophils scan 626 for activated platelets to initiate inflammation Neutrophil stunning by metoprolol reduces infarct size Inhibition of IP6K1 suppresses neutrophil-630 mediated pulmonary damage in bacterial pneumonia Platelet-neutrophil complex 633 formation-a detailed in vitro analysis of murine and human blood samples Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across 636 Individuals and Species Scrublet: Computational Identification of Robust enumeration of cell subsets 640 from tissue expression profiles Sex differences in neutrophil 642 biology modulate response to type I interferons and immunometabolism clustifyr: an R package for automated 645 single-cell RNA sequencing cluster classification Estimating the population 647 abundance of tissue-infiltrating immune and stromal cell populations using gene expression Reference-based analysis of lung single-cell 650 sequencing reveals a transitional profibrotic macrophage Circulating platelet-neutrophil aggregates 652 play a significant role in Kawasaki disease P-selectin-654 mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell 655 disease Platelets Aggregate With 657 Neutrophils and Promote Skin Pathology in Psoriasis myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes Polymorphonuclear 662 granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells 663 and expansion in advanced disease Amplified expression profiling of 665 platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease Transcript profiling of 668 human platelets using microarray and serial analysis of gene expression RhoH/TTF negatively 670 regulates leukotriene production in neutrophils A transcriptomic 672 reporter assay employing neutrophils to measure immunogenic activity of septic patients' plasma Neutrophilia as prognostic 677 biomarker in locally advanced stage III lung cancer Peripheral blood biomarkers 680 correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies Neutrophil-683 lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer 687 (NSCLC) treated with nivolumab Baseline neutrophil-689 to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced 690 melanoma treated with nivolumab Arginase I Production in 692 the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-693 Specific T-Cell Responses Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma Targeting both tumour-700 associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves 701 chemotherapeutic responses in pancreatic ductal adenocarcinoma Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and 704 Resistance to Sorafenib Platelet gene expression 706 and function in patients with COVID-19 Aggregates in COVID-19 Patients Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients Figure 1. Identification of NPAs in both NSCLC patients and healthy donors' peripheral blood. 718 (A) Gating strategy on ISX to identify CD36 + ITGA2B + NPAs from CD15 + CD14 -neutrophils in NSCLC 719 patients' peripheral whole blood (one representative data of n= 6 NSCLC patients' blood) Images were 721 taken with X40 objective. CD15: Neutrophil marker; CD14: Monocyte marker; ITGA2B, CD36, CD62P: 722 Platelet markers. (C) May-Grünwald-Giemsa coloration on NSCLC patient's whole blood smear. X100 723 magnification. Dark arrows show the presence of platelets aggregated to neutrophil (NPAs). Neutrophil is 724 evidenced by segmented nucleus in dark purple Box plot representing the frequency of non-coincidental CD15 + CD14 -CD36 + ITGA2B + NPAs (among all 726 neutrophils) in whole blood of NSCLC (n=6) patients and HDs (n=10), determined by ISX. Difference in 727 terms of frequency of NPAs between NSCLC patients and HDs was assessed by the Wilcoxon rank-sum A) Box plot representing ssGSEA enrichment scores of the Raghavachari platelet signature Differential enrichment of platelet signature between LDN and NDN groups was 738 assessed by the Wilcoxon rank-sum (Mann-Whitney) statistical test. P-value was displayed on graphs Schematic representation of Ficoll density gradient centrifugation of human whole blood 740 showing the separation of the low-density fraction (containing PBMCs) from the normal-density fraction 741 (containing mostly granulocytes) NPAs from LDN gate in the 745 PBMC fraction and NDN gate in the granulocyte fraction. Images were taken with X40 objective. CD15: 746 Neutrophil marker; CD14: Monocyte marker Cohort of PAAD and LIHC cancer patients were cut at tercile values based on mean 819 expression of "Neutrophil_Ponzetta" or "NPA_12" signature, yielding two groups